Short Communication: Discordance in Drug Resistance Mutations Between Blood Plasma and Semen or Rectal Secretions Among Newly Diagnosed HIV-1-Infected Thai Men Who Have Sex with Men.
PMID: 29756454
2018
AIDS research and human retroviruses
Abstract: Three participants had DRAMs in anogenital compartments that were not detected in blood plasma-one had DRAMs in semen that was not detected in blood plasma (I54FI) and two had DRAMs in rectal secretions that was not detected in blood plasma (I47IM; K70N, L74I, Y115F, M184V, K103N, V108I, and H221Y).
Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study.
Abstract: The most common emergent RAMs to NRTIs were M184V/I (42.3%) and K65R (28.2%), and those to nNRTIs were Y181C (42.3%), K103N (15.5%), G190A/E/Q (12.7%),
Discussion: Apart from the common emergent RAMs observed in patients with first-line treatment failure in previous studies, such as M184V/I (42.3%), Y181C (42.3%), and K103N (15.5%), 28.2% of our patients with virological failure harbored K65R mutation, which was 6 times more likely to occur in those individuals receiving regimens containing TDF/FTC or TDF plus lamivudine and nevirapine.
[Study on the relationship between HIV drug resistance and CD4(+)T cell counts among antiretroviral therapy patients with low viral load].
PMID: 29973007
2018
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: The second one was K103N (NNRTI), and the percentage was 22.5% (50 cases).
Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
PMID: 29977795
2018
African journal of laboratory medicine
Introduction: The most common non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations were K103N (58.1%), Y181C (41.9%) and G190A (6.5%), and the most frequent nucleoside reverse transcriptase inhibitor (NRTI) mutation was M184V (61.3%).
Discussion: In the present study, the K103N mutation was not detected from the mixed clone at 1% of minority variant level of control plasmids from 520 reads.
Discussion: Some minority K103N mutations could have been missed in this study.
Discussion: The H221Y mutation could also impact clinical outcomes as Y
Antiretroviral resistance among HIV-1 patients on first-line therapy attending a comprehensive care clinic in Kenyatta National Hospital, Kenya: a retrospective analysis.
PMID: 30061964
2018
The Pan African medical journal
Abstract: They included K103N (n = 10), G190A (n = 1), Y181C (n = 1) and Y188L (n = 1).
Result: They included K103N (n=10), G190A (n=1), Y181C (n=1) and Y188L (n=1) (Table 2).
Table: K103N
Discussion: The most prevalent NNRTI mutation that was detected in the studied population was K103N, which is associated with the use of Nevirapine - also a major component of first line regimens in Kenya.
Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.
PMID: 30079168
2018
Journal of public health in Africa
Result: K103N was detected more in children (11.1%) than in mothers but did not confer resistance to ARV used.
Discussion: (2015) where K103N was associated to resistance to NVP and EFV, in this study this mutation was not associated to any NNRTI.
Discussion: Some studies also found K103N and Y181C in individuals with subtypes A, B, C, F and CRF02_AG who developed resistance to NVP, ETR, and EFV.
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Introduction: One patient acquired virus with the Q148R mutation, conferring phenotypic resistance to RAL, EVG and CAB, in association with the K103N, E138G, and K238T, conferring cross-resistance to non-nucleoside RT inhibitors (NNRTIs).
Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Abstract: The most common NRTI mutation found was M184 V; K103 N and A98G were the most common NNRTI mutations seen.
Discussion: K103 N and V106A are major mutations associated with
Discussion: For the mothers who were on ART after prophylaxis in the PMTCT programme, the HIV-1 drug resistance associated mutations seen were dominated by M184 V for NRTIs and Thymidine Analogue-Associated Mutations (TAMS) including M41 L and T215Y; and K103 N with A98G for NNRTIs.
HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013.
Result: Taken together, the G190A/S/E mutations were most prominent (seven of the 12 NNRTI mutations), followed by the K103N, Y181I/C and K101E substitutions (two, two and one, respectively).
Result: Two had K103N, one G190S and one Y181C, all representing resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI).
Discussion: The specific NNRTI associated mutations found in this study (K103N, G109S and Y181C) have been reported to account for the most
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.
Discussion: After evaluating 184 genotyping tests from patients during the first virologic failure, we found a higher prevalence of subtype B, of the M184 V/I and K103 N mutations, as well as a high frequency of NRTI(t) and NNRTI-associated mutations, with no impact on virologic suppression.
Discussion: The K103 N/S mutation was documented in most genotypic sequences, due to the frequent use of EFV as the primary NNRTI in the first-line therapy for more than a decade in Brazil.
HIV mutation literature information.
PMID: 
2018
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT